Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$116 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
27.3
Industry P/E
--
EV/EBITDA
0.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2.4
Face value
--
Shares outstanding
56,651,840
CFO
$-291.92 Mln
EBITDA
$-368.11 Mln
Net Profit
$-362.06 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Leap Therapeutics (LPTX)
| -45.0 | 243.9 | 458.3 | -50.0 | -31.8 | -39.6 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Leap Therapeutics (LPTX)
| -30.4 | -7.9 | -86.1 | 44.0 | 100.9 | -44.0 | -67.7 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Leap Therapeutics (LPTX)
|
1.6 | 116.1 | 0.4 | -98.2 | -10,576.5 | -834.6 | -- | 27.3 |
| 4.4 | 96.3 | -3.6 | -204.4 | 4,048.0 | -- | -- | 0.9 | |
| 54.7 | 4,499.0 | 0.0 | -292.8 | -7,205,162.5 | -28.7 | -- | 4.7 |
Cypherpunk Technologies Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead clinical stage drug candidate includes DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1,... which is in various ongoing clinical trials for treating esophagogastric and gynecologic cancers, and colorectal cancer. The company also develops FL-501, a monoclonal antibody that inhibits GDF-15 protein that is in preclinical trial. It has an option and license agreement with Adimab, LLC and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as Leap Therapeutics, Inc. and changed its name to Cypherpunk Technologies Inc. in November 2025. The company was incorporated in 2011 and is based in Cambridge, Massachusetts. Read more
CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
Mr. Douglas E. Onsi J.D.
CFO, General Counsel, Treasurer & Secretary, President, CEO & Director
Mr. Douglas E. Onsi J.D.
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Leap Therapeutics Inc (LPTX) is $1.58 (NASDAQ) as of 11-Dec-2025 09:30 EDT. Leap Therapeutics Inc (LPTX) has given a return of -31.8% in the last 3 years.
Since, TTM earnings of Leap Therapeutics Inc (LPTX) is negative, P/E ratio is not available.
The P/B ratio of Leap Therapeutics Inc (LPTX) is 27.25 times as on 11-Dec-2025, a 592 premium to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.76
|
3.38
|
|
2023
|
-1.37
|
1.86
|
|
2022
|
-0.09
|
0.09
|
|
2021
|
-0.90
|
0.34
|
|
2020
|
-5.07
|
0.25
|
The 52-week high and low of Leap Therapeutics Inc (LPTX) are Rs 3.58 and Rs 0.22 as of 03-Apr-2026.
Leap Therapeutics Inc (LPTX) has a market capitalisation of $ 116 Mln as on 11-Dec-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Leap Therapeutics Inc (LPTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.47
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.